Evelo Biosciences, Inc. (EVLO) News

Evelo Biosciences, Inc. (EVLO): $5.21

0.01 (+0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVLO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 453

in industry

Filter EVLO News Items

EVLO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EVLO News Highlights

  • For EVLO, its 30 day story count is now at 2.
  • Over the past 13 days, the trend for EVLO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest EVLO News From Around the Web

Below are the latest news stories about Evelo Biosciences Inc that investors may wish to consider to help them evaluate EVLO as an investment opportunity.

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January

Yahoo | January 17, 2022

Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced its strategic priorities and upcoming catalysts for 2022. “In 2021 we announced positive Phase 2 clinical data for our first SINTAX-based medicine EDP1815 in psoriasis, demonstrating that EDP1815 is a potential medicine that can be delivered orally t

Yahoo | January 4, 2022

Evelo Biosciences picked for addition to Nasdaq Biotechnology Index

No summary available.

Seeking Alpha | December 14, 2021

Evelo Biosciences Added to Nasdaq Biotechnology Index

CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the Company has been added to the NASDAQ Biotechnology Index ® (Nasdaq: NBI), effective prior to market open on December 20, 2021.

Intrado Digital Media | December 14, 2021

Goldman Sachs Group Inc. Purchases 12,716 Shares of Evelo Biosciences, Inc. (NASDAQ:EVLO)

Goldman Sachs Group Inc. boosted its position in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) by 90.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,779 shares of the companys stock after purchasing an additional 12,716 shares during the quarter. Goldman Sachs Group Inc.s holdings []

Transcript Daily | December 9, 2021

Evelo Biosciences Inc. (NASDAQ:EVLO) Down -3.06% Over A Week, Now Can The Stock Hit Well Above -$0.26?

In last trading session, Evelo Biosciences Inc. (NASDAQ:EVLO) saw 0.3 million shares changing hands with its beta currently measuring 1.57. Companys recent per share price level of $8.25 trading at -$0.16 or -1.90% at ring of the bell on the day assigns it a market valuation of $436.92M. That closing price of EVLOs stock is Evelo Biosciences Inc. (NASDAQ:EVLO) Down -3.06% Over A Week, Now Can The Stock Hit Well Above -$0.26? Read More »

Marketing Sentinel | December 4, 2021

California State Teachers Retirement System Boosts Stock Holdings in Evelo Biosciences, Inc. (NASDAQ:EVLO)

California State Teachers Retirement System lifted its stake in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) by 20.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,923 shares of the companys stock after acquiring an additional 7,188 shares during the quarter. California State Teachers Retirement [] The post California State Teachers Retirement System Boosts Stock Holdings in Evelo Biosciences, Inc. (NASDAQ:EVLO) appeared first on ETF Daily News .

ETF Daily News | November 29, 2021

Marshall Wace LLP Reduces Stock Position in Evelo Biosciences, Inc. (NASDAQ:EVLO)

Marshall Wace LLP reduced its holdings in Evelo Biosciences, Inc. (NASDAQ:EVLO) by 58.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 62,602 shares of the companys stock after selling 87,324 shares during the period. Marshall Wace LLPs holdings in Evelo Biosciences were worth $861,000 at the end of the most recent reporting period. []

Transcript Daily | November 26, 2021

Evelo Biosciences, Inc. (NASDAQ:EVLO) Stake Lowered by AQR Capital Management LLC

AQR Capital Management LLC cut its holdings in Evelo Biosciences, Inc. (NASDAQ:EVLO) by 72.6% in the second quarter, HoldingsChannel reports. The firm owned 13,092 shares of the companys stock after selling 34,616 shares during the period. AQR Capital Management LLCs holdings in Evelo Biosciences were worth $180,000 as of its most recent SEC filing. A []

Transcript Daily | November 24, 2021

Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that management will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th, 2021 at 6:20 a.m. ET (11:20 a.m. GMT). A live audio webcast of the presentation will be available under “News and Events” in the Invest

Yahoo | November 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5811 seconds.